Biotest: Q3 2014 Results (Biotest) - Nov 15, 2014 - "ASH abstract: Indatuximab Ravtansine (BT-062)"; "BT-062 is well tolerated with LenDEX (Lenalidomide/Dexamethason)"; "Very good responses in patients with relapsed and / or refractory multiple myeloma and patients who do not respond to standard therapy"; "Overall response rate (ORR) is 78% including: 8% complete remissions, 28% very good partial remissions, 42% partial remissions"
P2 data • Multiple Myeloma • Oncology
|